Archive

Much-needed new drug approved for deadliest blood cancer

Written by Charlie King | 3 Dec 2025

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer. The… read more.

New insights on uproleselan for AML treatment to Be unveiled by GlycoMimetics at ASH 2024

Written by Charlie King | 10 Nov 2024

GlycoMimetics, Inc. announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of… read more.

Major discovery provides new hope for blood cancer patients

Written by Charlie King | 13 May 2022

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within… read more.

Patient possibly cured of HIV infection by special stem-cell transplant

Written by Charlie King | 23 Feb 2022

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping… read more.

European Commission approval for Venclyxto + a hypomethylating agent for newly diagnosed acute myeloid leukemia – AbbVie

Written by Charlie King | 3 Jun 2021

AbbVie announced that the European Commission (EC) has approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly… read more.

EU CHMP recommends approval of Onureg for acute myeloid leukemia – Bristol Myers Squibb

Written by Charlie King | 30 Apr 2021

Bristol Myers Squibb has announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Onureg (azacitidine tablets; CC-486) as a… read more.

FDA approval of additional indication for Vyxeos for the treatment of secondary acute myeloid leukemia in pediatric patients – Jazz Pharma

Written by Charlie King | 13 Apr 2021

Jazz Pharmaceuticals plc has announced that the FDA approved a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid… read more.